Co-Authors
This is a "connection" page, showing publications co-authored by NAOTO T UENO and MICHAEL C. STAUDER.
Connection Strength
0.722
-
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213.
Score: 0.167
-
International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018; 9(8):1437-1447.
Score: 0.162
-
Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol. 2017 04; 18(4):e228-e232.
Score: 0.151
-
Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Ann Surg Oncol. 2022 Oct; 29(10):6381-6392.
Score: 0.055
-
Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. Pract Radiat Oncol. 2019 Nov; 9(6):402-409.
Score: 0.044
-
Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. Surg Clin North Am. 2018 Aug; 98(4):787-800.
Score: 0.041
-
Impact of Statin Use on Outcomes in Triple Negative Breast Cancer. J Cancer. 2017; 8(11):2026-2032.
Score: 0.038
-
Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer. 2015 Dec 15; 121(24):4324-32.
Score: 0.034
-
Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. Springerplus. 2014; 3:166.
Score: 0.031